Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

IDYA

Ideaya Biosciences Inc

May 06 • 04:00PM ET

28.74

-0.06 -0.21 %

Healthcare • Biotechnology • USA • Mid • NASD

May 05, 8:15 AMIdeaya Biosciences reports fiscal Q1 2026 results with non-GAAP EPS $-1.11 (-35% YoY) and revenue $6.6M, misses EPS but beats revenue estimates, affirms cash runway into 2030

Peers: EXEL INCY NBIX BPMC ARGX FATE YMAB NERV GOSS ENTA

| Held by: VTI IWM XBI VXF IWN IBB VTWO SCHA DFAS VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.60	Insider Own	5.97%	Shs Outstand	87.86M	Perf Week	2.46%
Market Cap	2.52B	Forward P/E	-	EPS next Y	-3.64	Insider Trans	0.96%	Shs Float	82.57M	Perf Month	-7.02%
Enterprise Value	1.58B	PEG	-	EPS next Q	-1.05	Inst Own	105.25%	Short Float	12.79%	Perf Quarter	-13.64%
Income	-140.06M	P/S	11.20	EPS this Y	-232.48%	Inst Trans	1.81%	Short Ratio	8.84	Perf Half Y	-8.35%
Sales	225.27M	P/B	2.69	EPS next Y	14.54%	ROA	-13.14%	Short Interest	10.56M	Perf YTD	-16.86%
Book/sh	10.67	P/C	2.59	EPS next 5Y	-28.98%	ROE	-10.92%	52W High	39.28 -26.83%	Perf Year	61.92%
Cash/sh	11.08	P/FCF	-	EPS past 3/5Y	3.17% 1.64%	ROIC	-14.51%	52W Low	16.82 70.87%	Perf 3Y	50.71%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	62.54% 62.11%	Gross Margin	97.96%	Volatility	4.02% 5.60%	Perf 5Y	51.26%
Dividend TTM	-	EV/Sales	7.01	EPS Y/Y TTM	55.95%	Oper. Margin	-81.44%	ATR (14)	1.56	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.34	Sales Y/Y TTM	3118.14%	Profit Margin	-62.17%	RSI (14)	39.64	Recom	1.22
Dividend Gr. 3/5Y	- -	Current Ratio	11.34	EPS Q/Q	-35.99%	SMA20	-6.40%	Beta	-0.04	Target Price	52.56
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-9.96%	Rel Volume	0.73	Prev Close	28.80
Employees	145	LT Debt/Eq	0.03	Earnings	May 05 BMO	SMA200	-5.78%	Avg Volume	1.20M	Price	28.74
IPO	May 23, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-12.26% 30.20%	Trades		Volume	877,320	Change	-0.21%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-26	Resumed	UBS	Buy	$50
Nov-24-25	Initiated	Truist	Buy
Sep-18-25	Initiated	Guggenheim	Buy	$50
Sep-04-25	Initiated	Citizens JMP	Mkt Outperform	$41
Sep-04-25	Initiated	Barclays	Overweight	$40
Jul-22-25	Initiated	TD Cowen	Buy
Jul-10-25	Resumed	Goldman	Neutral	$25
Jun-26-25	Initiated	Wells Fargo	Overweight	$44
Nov-18-24	Initiated	Stephens	Overweight	$51
Nov-05-24	Downgrade	Leerink Partners	Outperform → Market Perform	$27
Oct-24-24	Initiated	UBS	Buy	$50
Oct-15-24	Initiated	Cantor Fitzgerald	Overweight
Jul-08-24	Initiated	Mizuho	Outperform	$50
Mar-08-24	Initiated	BTIG Research	Buy	$55
Aug-08-23	Initiated	SVB Securities	Outperform	$33
May-24-23	Initiated	Goldman	Buy	$32
Apr-24-23	Upgrade	Stifel	Hold → Buy	$18 → $24
Mar-23-23	Initiated	Berenberg	Buy	$26
Feb-28-23	Initiated	RBC Capital Mkts	Outperform	$25
Dec-28-22	Initiated	CapitalOne	Overweight	$29

Show Previous Ratings

May-05-26 06:00AM	IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update (PR Newswire)
Apr-30-26 06:00AM	IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program (PR Newswire)
Apr-21-26 10:15AM	IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma (PR Newswire) -5.27%
Apr-14-26 04:55AM	Novo teams with OpenAI; Ideaya gets muted response to eye drug data (BioPharma Dive)
Apr-13-26 10:55AM	Ideaya Biosciences Surges On Promising Results For Hard-To-Treat Melanoma (Investor's Business Daily) +7.61%
07:21AM	Loading…
07:21AM	Ideaya Biosciences Stock Jumps 15% on Eye Cancer Therapy Trial Results (Barrons.com)
06:00AM	These Stocks Are Today's Movers: Goldman Sachs, Sandisk, Exxon Mobil, Nvidia, Ideaya, and More (Barrons.com)
06:00AM	IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma (PR Newswire)
Apr-10-26 04:05PM	IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026 (PR Newswire)
Apr-06-26 06:00AM	IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer (PR Newswire)
Mar-30-26 06:00AM	IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma (PR Newswire)
Mar-27-26 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.08%
Mar-22-26 10:00AM	IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial (PR Newswire)
Mar-18-26 06:00AM	IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs (PR Newswire)
Mar-09-26 09:10AM	DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier (Zacks) +5.69%
06:00AM	Loading…
06:00AM	IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update (PR Newswire)
Mar-06-26 10:22AM	IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC (Insider Monkey)
Feb-27-26 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Feb-25-26 06:00AM	IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC (PR Newswire)
Feb-23-26 02:28PM	IDEAYA Biosciences Teases Late-March Phase III Darovasertib Readout, ADC Updates, New KAT6/7 Phase I Launch (MarketBeat)
01:13PM	IDEAYA Biosciences Teases End-of-March Data for Darovasertib Combo at Citi Oncology Summit (MarketBeat)
06:00AM	IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer (PR Newswire)
Feb-17-26 06:00AM	IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update (PR Newswire)
Feb-02-26 06:00AM	IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events (PR Newswire) +5.81%
Jan-30-26 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jan-13-26 09:21AM	Day One Biopharmaceuticals (DAWN) Surges 26.7%: Is This an Indication of Further Gains? (Zacks)
Jan-11-26 12:00PM	IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-05-26 06:00AM	IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-11-25 06:00AM	IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma (PR Newswire)
Dec-10-25 06:00AM	IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers (PR Newswire)
07:00PM	Loading…
Dec-04-25 07:00PM	IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance (Business Wire)
Dec-01-25 06:00AM	IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types (PR Newswire)
Nov-28-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-24-25 06:00AM	IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events (PR Newswire)
Nov-20-25 04:15PM	Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth (Business Wire)
Nov-04-25 06:00AM	IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
Oct-31-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Oct-27-25 06:00AM	IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events (PR Newswire) +10.93%
Oct-20-25 06:30AM	IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025 (PR Newswire)
06:00AM	IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress (PR Newswire)
Oct-17-25 09:55PM	Citizens JMP Remains Bullish on IDEAYA Biosciences (IDYA) (Insider Monkey) +5.67%
Oct-15-25 09:11AM	Next-Generation Targeted Therapies Reshape Precision Oncology Landscape (PR Newswire)
Oct-08-25 12:57AM	J.P. Morgan Remains Bullish on IDEAYA Biosciences (IDYA) (Insider Monkey)
Sep-26-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Sep-10-25 12:59AM	Citizens JMP Initiates IDEAYA Biosciences (IDYA) With a Buy Rating (Insider Monkey)
Sep-08-25 09:30AM	Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market (PR Newswire) -13.88%
08:00AM	IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy in MTAP-Deletion Urothelial Cancer (PR Newswire)
06:00AM	IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma (PR Newswire)
Sep-07-25 12:00PM	IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer (PR Newswire)
Sep-04-25 06:00AM	IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy in MTAP-Deletion Non-Small Cell Lung Cancer (PR Newswire)
Sep-03-25 06:00AM	IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors (PR Newswire)
Sep-02-25 06:00AM	Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide (PR Newswire)
Aug-29-25 02:00PM	IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress (PR Newswire)
06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-25-25 06:00AM	IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events (PR Newswire)
Aug-18-25 06:00AM	IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025 (PR Newswire)
Aug-05-25 06:00AM	IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
Aug-01-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jul-24-25 11:47PM	TD Cowen Bullish on Ideaya's (IDYA) Oncology Pipeline (Insider Monkey) +5.08%
09:25AM	IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma (PR Newswire)
Jul-23-25 06:00AM	IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy (PR Newswire) +7.31%
Jul-22-25 01:01PM	IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC (PR Newswire)
Jul-21-25 06:00AM	IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event (PR Newswire)
Jun-27-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-26-25 09:49AM	General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls (The Fly)
Jun-02-25 06:00AM	IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events (PR Newswire) +6.69%
May-30-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-06-25 06:05AM	IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update (PR Newswire) -13.29%
06:00AM	IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors (PR Newswire)
May-05-25 07:51AM	Why IDEAYA Biosciences, Inc. (IDYA) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential (Insider Monkey)
Apr-28-25 06:00AM	IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events (PR Newswire)
Apr-27-25 09:22AM	Immunocore Holdings: A Name On My Watch List (Seeking Alpha)
Apr-25-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-16-25 08:52AM	Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later (Seeking Alpha)
Apr-14-25 06:00AM	IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma (PR Newswire)
Apr-10-25 06:00AM	IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy Combination in MTAP-Deletion Urothelial Cancer (PR Newswire)
Apr-02-25 11:49AM	Hospitals Experience FOMO In Adopting Delcath's PHP Treatment (Seeking Alpha) +10.70%
11:12AM	Why Ideaya Biosciences Is Down Despite Many Positives (Seeking Alpha)
Apr-01-25 06:00AM	IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events (PR Newswire) -9.83%
Mar-31-25 06:00AM	IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma (PR Newswire)
Mar-28-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Mar-26-25 06:00AM	IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor (PR Newswire)
Mar-20-25 09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
Mar-05-25 02:45PM	IDEAYA Biosciences, Inc. (IDYA) Partners with ATTMOS for AI-Driven Drug Discovery Platform (Insider Monkey)
Mar-03-25 06:00AM	IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets (PR Newswire) -7.00%
Feb-28-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Feb-14-25 09:35AM	Down -8.63% in 4 Weeks, Here's Why You Should You Buy the Dip in IDEAYA Biosciences (IDYA) (Zacks)
Feb-13-25 07:15AM	IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss (Zacks) -5.42%
06:05AM	IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (PR Newswire)
06:00AM	IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy and IDE397 in MTAP-Deletion NSCLC (PR Newswire)
Feb-10-25 12:00PM	All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to Buy (Zacks)
06:00AM	IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer (PR Newswire)
Jan-31-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jan-30-25 05:07PM	Here's Why IDEAYA Biosciences, Inc. (IDYA) Will Double in 2025 (Insider Monkey)
Jan-27-25 06:00AM	IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events (PR Newswire)
Jan-12-25 12:00PM	IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance (PR Newswire)
Dec-29-24 06:00AM	IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors (PR Newswire)
Dec-27-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-17-24 06:00AM	IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma (PR Newswire)
Dec-16-24 06:00AM	IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers (PR Newswire)

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stein Jeffrey	Director	Mar 02 '26	Buy	32.96	50,000	1,647,890	54,281	Mar 02 07:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IDYA

Ideaya Biosciences Inc

Upgrade your Finviz experience